CLAREMONT, Calif., Jan. 29, 2007 (PRIME NEWSWIRE) -- Kiwa Bio-Tech Products Group Corporation (OTCBB:KWBT) announces that it has appointed Mr. Wenbin Li as the Vice President in charge of marketing and sales.
On January 20, 2007, Kiwa's Board of Directors passed the resolution to appoint Mr. Wenbin Li as the Vice President in charge of marketing and sales of the whole group.
Mr. Wenbin Li holds a master's degree from Henan Agricultural University. General Manager of Tianjin Challenge Feed Co. Ltd. since 1999, his company generated RMB 150 million (about USD 18.75 Million) of sales revenue on an average year. Mr. Li became the General Manager of Tianjin KIWA Feed Co., Ltd after its establishment last July. Up to December 2006, Tianjin Kiwa sold altogether approximately 7,000 metric tons of feed products, realizing about RMB 20 million (USD 2.5 Million) of sales revenue. Mr. Li will be in charge of the marketing and sales of Kiwa's biological products after this nomination. He said that he would start to adjust the existing marketing and sales forces at once to make greater progress on sales in the year of 2007.
Mr. Wei Li, Chairman of the Board and CEO of Kiwa, stated: "Mr. Wenbin Li has a wealth of experience in marketing and sales. Management believes that he can make full use of his experiences to promote our bio-fertilizer products in domestic market while leading Tianjin Kiwa to generate more profit."
About Kiwa Bio-Tech Products Group Corporation
The Company develops, manufactures, and distributes and markets innovative, cost-effective, and environmentally safe bio-technological products for agricultural and natural resources and environmental conservation. The Company has acquired the rights to manufacture and market AF-01 Anti-viral Aerosol Agent for use in preventing (blocking) bird-flu disease in Chinese and international markets. The Company has excellent relations with government authorities in China and has developed several innovative, high margin products, while continuing to grow through internal and external product development.
For more information about the Company, please visit the Company's website at http://www.kiwabiotech.com.
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.